We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PolyTherics and MacroGenics Sign Collaboration Agreement
News

PolyTherics and MacroGenics Sign Collaboration Agreement

PolyTherics and MacroGenics Sign Collaboration Agreement
News

PolyTherics and MacroGenics Sign Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PolyTherics and MacroGenics Sign Collaboration Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PolyTherics Ltd has announced the initiation of a research collaboration with MacroGenics Inc., a leader in next-generation antibody platforms and therapeutics.

PolyTherics has a range of proprietary site-specific PEGylation technologies that can improve the duration of action of a broad range of biotherapeutics. MacroGenics’ proprietary Dual-Affinity Re-Targeting (DART™) technology is a bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. PolyTherics has already shown that its TheraPEG™ PEGylation technology can extend the half-life of antibody fragments without loss of activity in vitro.

Under the research collaboration agreement with MacroGenics, PolyTherics will apply its site-specific PEGylation technologies to an initial DART protein which will then be evaluated by MacroGenics. MacroGenics has the option to use PolyTherics’ PEGylation technologies for additional DART product candidates in the future. PolyTherics has also granted MacroGenics an option to license the PEGylation technologies to enable further development and commercialization of PEGylated DART proteins.

Dr Keith Powell, Chief Executive Officer of PolyTherics said “We are very excited about working with a leader in the bi-specific antibody fragment space. Our technologies allow for site-specific PEGylation without the need for modification of the protein. We are looking forward to a productive partnership with MacroGenics.”

Dr Scott Koenig, MacroGenics’ President and Chief Executive Officer said “PolyTherics’ unique PEGylation technology appears to be well suited to enhance the pharmacologic properties of MacroGenics’ bi-specific DART proteins, furthering our commitment to produce truly ‘best-in-class’ biotherapeutics. We look forward to collaborating with PolyTherics.”
Advertisement